- Home
- PRTG
PRTG
Portage Biotech Inc.
as 12-23-2024 10:47am EST
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.
| Founded: | 1973 | Country: | British Virgin Islands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 4.7M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -63.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.10 - $40.80 | Next Earning Date: | 11-26-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Portage Biotech Inc. News
PRTG Breaking Stock News: Dive into PRTG Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
Top Premarket Decliners
MT Newswires
6 days ago
Top Midday Gainers
MT Newswires
6 days ago
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday
MT Newswires
6 days ago
Portage Biotech Shares Soar Over 212% in Premarket Activity After Announcing Entering Letter of Intent With Immunova
MT Newswires
6 days ago
Top Premarket Gainers
GlobeNewswire
6 days ago
Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd
GlobeNewswire
11 days ago
Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter
GlobeNewswire
a month ago
Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024
Compare PRTG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRTG Portage Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.